tirzepatide vs cagrisema tirzepatide: which next-generation weight loss treatment wins? CagriSema Delivers 23% Weight Loss

A meta-analysis of nine randomized controlled trials with a combined total of 352 subjects with NAFLD found probiotic therapy reduced liver enzyme and total cholesterol levels

For glycemic control, the mean reduction in HbA1c across most T2DM subgroups approaches or reaches the commonly referenced threshold for clinical relevance of 0.5% 47 , and in key target populations (e.g., T2DM with obesity) can reach 0.81.0%, indicating clinically perceptible improvements

The demonstration of cardiorenal benefits with SGLT2i in clinical trials both for participants with CKD and type 2 diabetes and for those without [23,24,25] and the updated 2022 KDIGO guidelines recommending SGLT2i as first-line therapy for patients with CKD and type 2 diabetes regardless of glycemic control [6] have likely driven a shift toward their broader use for preventive cardiorenal protection and earlier implementation for patients with type 2 diabetes

She immediately stopped and called her OB/GYN in a panic